134 related articles for article (PubMed ID: 11420727)
21. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
22. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
23. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
24. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function.
Villa R; Morey L; Raker VA; Buschbeck M; Gutierrez A; De Santis F; Corsaro M; Varas F; Bossi D; Minucci S; Pelicci PG; Di Croce L
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1400-5. PubMed ID: 16432238
[TBL] [Abstract][Full Text] [Related]
25. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
27. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Matthews GM; Mehdipour P; Cluse LA; Falkenberg KJ; Wang E; Roth M; Santoro F; Vidacs E; Stanley K; House CM; Rusche JR; Vakoc CR; Zuber J; Minucci S; Johnstone RW
Blood; 2015 Nov; 126(21):2392-403. PubMed ID: 26447190
[TBL] [Abstract][Full Text] [Related]
28. Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation.
Insinga A; Pelicci PG; Inucci S
Cell Cycle; 2005 Jan; 4(1):67-9. PubMed ID: 15611639
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of histone deacetylase as a new mechanism of teratogenesis.
Menegola E; Di Renzo F; Broccia ML; Giavini E
Birth Defects Res C Embryo Today; 2006 Dec; 78(4):345-53. PubMed ID: 17315247
[TBL] [Abstract][Full Text] [Related]
30. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation.
Nebbioso A; Dell'Aversana C; Bugge A; Sarno R; Valente S; Rotili D; Manzo F; Teti D; Mandrup S; Ciana P; Maggi A; Mai A; Gronemeyer H; Altucci L
J Mol Endocrinol; 2010 Oct; 45(4):219-28. PubMed ID: 20639404
[TBL] [Abstract][Full Text] [Related]
31. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase as a therapeutic target.
Krämer OH; Göttlicher M; Heinzel T
Trends Endocrinol Metab; 2001 Sep; 12(7):294-300. PubMed ID: 11504668
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Warrell RP; He LZ; Richon V; Calleja E; Pandolfi PP
J Natl Cancer Inst; 1998 Nov; 90(21):1621-5. PubMed ID: 9811311
[TBL] [Abstract][Full Text] [Related]
34. Effects of the acute myeloid leukemia--associated fusion proteins on nuclear architecture.
Faretta M; Di Croce L; Pelicci PG
Semin Hematol; 2001 Jan; 38(1):42-53. PubMed ID: 11172539
[TBL] [Abstract][Full Text] [Related]
35. G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent.
Tonelli R; Sartini R; Fronza R; Freccero F; Franzoni M; Dongiovanni D; Ballarini M; Ferrari S; D'Apolito M; Di Cola G; Capranico G; Khobta A; Campanini R; Paolucci P; Minucci S; Pession A
Leukemia; 2006 Jul; 20(7):1307-10. PubMed ID: 16617320
[No Abstract] [Full Text] [Related]
36. Histone deacetylase inhibitors in APL and beyond.
Petrie K; Prodromou N; Zelent A
Curr Top Microbiol Immunol; 2007; 313():157-203. PubMed ID: 17217044
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylases as therapeutic targets in hematologic malignancies.
Melnick A; Licht JD
Curr Opin Hematol; 2002 Jul; 9(4):322-32. PubMed ID: 12042707
[TBL] [Abstract][Full Text] [Related]
38. Patterns of alpha-L-fucosidase in acute myeloid leukemia cells. Comparison with promyelocytic HL-60 cell line.
Dosbaa I; Bernard M; Foglietti MJ; Percheron F; Emiliani C
Carbohydr Res; 1992 Dec; 236():259-65. PubMed ID: 1291051
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of selective anticancer action of histone deacetylase inhibitors.
Insinga A; Minucci S; Pelicci PG
Cell Cycle; 2005 Jun; 4(6):741-3. PubMed ID: 15908787
[TBL] [Abstract][Full Text] [Related]
40. Role of histone deacetylases in acute leukemia.
Fenrick R; Hiebert SW
J Cell Biochem; 1998; 72 Suppl 30-31(S30-31):194-202. PubMed ID: 29345812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
